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Innate immunityThe gammaretrovirus, xenotropic murine leukemia virus-related virus (XMRV), replicates to high titers in
some human cell lines and is able to infect non-human primates. To determine whether APOBEC3 (A3) pro-
teins restrict XMRV infections in a non-human primate model, we sequenced proviral DNA from peripheral
blood mononuclear cells of XMRV-infected rhesus macaques. Hypermutation characteristic of A3DE, A3F
and A3G activities was observed in the XMRV proviral sequences in vivo. Furthermore, expression of rhesus
A3DE, A3F, or A3G in human cells inhibited XMRV infection and caused hypermutation of XMRV DNA. These
studies show that some rhesus A3 isoforms are highly effective against XMRV in the blood of a non-human
primate model of infection and in cultured human cells.clid Avenue NB40, Cleveland,
rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Viral infections of mammalian cells are subject to inhibition by a
diverse group of host restriction factors that target different stages
in viral replication cycles (Douville and Hiscott, 2010). Members of
the APOBEC3 (A3) family of host restriction factors deaminate deox-
ycytidines in the minus DNA strand of some retroviruses leading to
G to A hypermutation of the coding strand with potent suppression
of viral replication (Malim and Emerman, 2008). The xenotropic mu-
rine leukemia virus-related virus (XMRV) is a gammaretrovirus orig-
inally identiﬁed by a virus DNA microarray approach in a study of
human prostate cancer tissues obtained following radical prostatecto-
mies (Urisman et al., 2006). XMRV lacks an inhibitor of A3 proteins,
such as the HIV-1 Vif protein, and is therefore highly susceptible to in-
hibition by human (hu) A3G (Bogerd et al., 2011; Groom et al., 2010;
Paprotka et al., 2010; Stieler and Fischer, 2010). Prior studies on
huA3B, huA3F and murine (mu) A3 produced mixed results, possiblyreﬂecting different experimental conditions such as levels of A3 pro-
teins that were expressed or cell types studied (Bogerd et al., 2011;
Groom et al., 2010; Paprotka et al., 2010; Stieler and Fischer, 2010).
Evidence of XMRV infection has been reported in patients with
prostate cancer (PCa) (Arnold et al., 2010; Danielson et al.,
2010; Schlaberg et al., 2009; Urisman et al., 2006), chronic fatigue
syndrome-myalgic encephalomyelitis (CFS-ME) (Lombardi et al.,
2009), immunosuppressed with respiratory tract infections (Fischer et
al., 2010) and normal healthy controls (Lombardi et al., 2009). Howev-
er, many studies have failed to detect XMRV in humans raising the issue
of laboratory contamination as a source of the infections [reviewed in
Stoye et al., 2010]. Furthermore, the recombinant origin of XMRV in a
cell line derived from human prostate tumor cells implanted in mice
has been described (Paprotka et al., 2011). Here we sought to deter-
mine the ability of A3 proteins to mutate XMRV DNA in a non-human
primate model of infection. In humans, A3G and A3F are widely
expressed in hematopoietic cell populations, including T cells, B cells,
and myeloid cells and the mRNA level of A3G is higher than that of
A3F mRNA (Koning et al., 2009; Refsland et al., 2010). Accordingly,
XMRV DNA would be expected to exhibit evidence of A3 editing in its
sequence if recovered from these cell populations. We show a
high prevalence of G to A mutations in XMRV proviral sequences
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mediated mutagenesis. Furthermore, most of the G to A mutations
occurred in the context of GA and GC dinucleotides. In contrast,
HIV-1 mutations typically occur within GG and GA dinucleotides in
human PBMC (Janini et al., 2001; Kieffer et al., 2005). In addition,
we have determined that rhesus A3DE, A3G and A3F are active
against XMRV in cultured cells. Our results demonstrate that primate
A3 isoforms are effective host restriction factors against XMRV in the
blood cells of a non-human primate model of infection.
Results
XMRV proviral sequences isolated from infected rhesus macaques
contain extensive G→A mutations typical of A3 activity
To determine the effect of rhesus A3 on XMRV infections in vivo,
PBMC DNA samples from XMRV-infected animals were examined.
Three animals were infected with a high dose of virus by the intrave-
nous route (Onlamoon et al., 2011). Virus replication was transient
and the twomonkeys (RII-10 and RYh-10) that had detectable viremia,
as determined byRT-PCR,were used for these studies. Eighteen individ-
ual cDNA clones per animal of a 1.2 kb segment from the XMRV pol gene
were obtained from PBMC DNA by nested PCR. Single-round PCR was
unsuccessful due to low levels of virus replication (Materials and
methods). Most, but not all, of the cDNA clones showed extensive G to
A mutations when compared to the pol sequence of XMRV strain
VP62 (EF185282), the virus used as the inoculum. In animal RIl-10
there were 158 G to A mutations out of 21,510 nt sequenced in total
(Fig. 1), while in animal RYh-10 there were 507 G to A mutations out
of 21,510 nt sequenced (Fig. 2). These results are strong evidence of
A3 deaminase activity in vivo in PBMC. Surprisingly, in both animals
at least half of the A3 editing was in the context of GA→AA typical of
A3F activities. The next most frequent context for hypermutation was
GC→AC, typical of A3DE, resulting in 32.5% and 26.4% of the mutations
in animals RIl-10 and RYh-10, respectively. A3G, which results in
GG→AG hypermutation, and the primary mediator of XMRVmutagen-
esis in human PBMCs culture (Chaipan et al., 2011), caused only 3.8%
and 9.0% of the mutations in animals RIl-10 and RYh-10, respectively
(Figs. 1 and 2). Examining the sequencing results revealed aFig. 1.Hypermutation of XMRV DNA in rhesus macaque PBMC characteristic of A3 activity in
green, GT to AT in magenta and all other mutations in black. (B and C) Total numbers andcombination of different types of dinucleotide context for G→A muta-
tions in individual cDNA clones. The overall rate of mutagenesis was
0.9% for animal RIl-10 and 2.7% for animal RYh-10, respectively. These
ﬁndings are in contrast to XMRV infected human CEM and H9 T cell
lines in which 76.5% and 93% were GG→AG mutations typical of A3G
activity(Paprotka et al., 2010). In Mus pahari, XMRV infections caused
G→A mutations in gag gene in spleen as a result of muA3 activity, al-
though in an unknown dinucleotide context (Sakuma et al., 2011).
A comparison of XMRV sequences of all 36 clones from both RIl-10
and RYh-10 showed a total of 97 individual G to A mutation sites
throughout the 1.2 kb region that were sequenced (Fig. 3A). A Venn
diagram showed that mutations at 22 sites were shared in the
XMRV sequences from both animals, possibly representing “hotspots”
for A3 editing in XMRV genome (Fig. 3B). Hypermutation of XMRV in
DU145 cells, the cell line used to produce the viral stock, occurs at a
low frequency (Paprotka et al., 2010). However, each macaque also
showed characteristic mutation proﬁles. Sixty-six editing sites were
unique to animal RYh-10 while ten editing sites were only identiﬁed
in animal RIl-10. Importantly, these results provide evidence that the
G to A mutations were the result of in vivo mutagenesis and rule out
the possibility that these mutations could have existed in the virus
stock used to infect the animals.
A possible mechanism responsible for the A3-mediated viral re-
striction is the accumulation of deleterious mutations in the viral ge-
nome, including nonsense mutations. Nucleotides 126–1203 of the
1.2 kb region overlap with the 5′-terminal part of the open reading
frame (ORF) of XMRV reverse transcriptase (RT) gene. We were
able to identify a total of 5 newly generated stop codons due to G to
A transition at different locations in the pol open reading frame.
These nonsense mutations, mediated by different isoforms of rhA3
proteins, occurred at different frequencies in the two macaques
(Table 1). Nonsense mutation at position 409 was exclusively identi-
ﬁed in RYh-10 and thus resulted in production of shortened and non-
functional XMRV RT in 8 out of 18 clones. The other 4 nonsense mu-
tations (at positions 224, 643, 682 and 964) were only identiﬁed in
RIl-10, each at different frequencies. Seven of the clones from RIl-10
contained more than one nonsense mutation. Altogether, only 3 of
18 clones from RIl-10 have the potential to encode full length
RT. The other clones encode RT polypeptides truncated at differentanimal RIl-10. (A) GG to AC mutations were labeled in red, GA to AA in cyan, GC to AC in
the sequence context of mutations are shown.
Fig. 2. Hypermutation of XMRV DNA in rhesus macaque PBMC characteristic of A3 activity in animal RYh-10. (A) GG to AC mutations were labeled in red, GA to AA in cyan, GC to AC
in green, GT to AT in magenta and all other mutations in black. (B and C) Total numbers and the sequence context of mutations are shown.
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duce the production of infectious progeny virus by disrupting genes
of key enzymes essential for viral replication.
XMRV is susceptible to rhA3 isoforms in cultured cells
To address whether different rhA3 isoforms are indeed able to ef-
fectively inhibit XMRV infectivity, we performed a single-cycle infec-
tivity assay in 293T cells as described previously (Bogerd et al., 2011).
In brief, 293T cells were co-transfected with the MLV-based luciferase
indicator construct pFB-Luc, together with plasmids encoding the
XMRV Env protein and XMRV Gag-Pol and also different members
of the human (hA3G) or rhesus (rhA3B, rhA3DE-I, rhA3DE-II, rhA3G
and rhA3F) (Virgen and Hatziioannou, 2007) A3 family. The empty
parental vector served as a control. When XMRV virions released
from transfected producer cells were used to infect naïve 293T target
cells, we observed very efﬁcient inhibition of XMRV infectivity by not
only rhA3G but also by both isoforms of rhA3DE, rhA3DE-I and
rhA3DE-II, as well as rhA3F (Fig. 4A). Interestingly, rhA3B, differed
from human A3B in being an ineffective inhibitor of XMRV infection
(Bogerd et al., 2011; Groom et al., 2010; Paprotka et al., 2010; Stieler
and Fischer, 2010).
To prove that rhA3DE-I, rhA3DE-II, rhA3F and rhA3G are indeed
able to effectively edit newly formed proviruses during acute XMRV
infection in cell culture, we generated XMRV virions containing
these rhA3 isoforms with the same co-transfection method in 293T
cells and then used the resultant XMRV virions to infect naïve 293T
cells. Fourteen independent 400-bp segments of the ﬁreﬂy luciferase
gene present in the newly formed proviruses were then recovered
from genomic DNA by PCR and subjected to sequencing analysis. As
expected, most (88.8%) of the mutations caused by rhA3F were G to
A transitions in the GA context (Figs. 4D and G). Similarly, most
(65%) of the mutations caused by rhA3DE-I and rhA3DE-II were in
the GA context. In addition, however, 20% and 29.7% of the mutations
caused by rhA3DE-I and rhA3DE-II, respectively, were in the GC con-
text (Figs. 4B, C and G). In contrast, rhA3G caused 85% of the G to A
mutations in the context of GG, as expected (Figs. 4E and G). In the
control cells infected by XMRV virions produced in the absence of ec-
topic A3 proteins, almost no mutations were detected (Fig. 3F). It isworth noting that the human isoforms of A3G and A3B (but not
A3F) were active against XMRV (Bogerd et al., 2011), while rhesus
A3F and A3G (but not rhA3B) inhibited XMRV (Fig. 4). Our ﬁndings
support the notion that A3 members have been under strong positive
selective pressure during evolution resulting in different antiviral ac-
tivities in different mammalian species (Zennou and Bieniasz, 2006).
Discussion
Previously we reported that XMRV could be consistently detected
in CD4+ and CD8+ T cells and in NK cells from acutely IV infected
rhesus macaques (Onlamoon et al., 2011). Results presented here in-
dicate G to A substitutions in XMRV sequences characteristic of rhA3
editing in PBMC of rhesus macaques, which are consistent with previ-
ous studies showing that XMRV is highly susceptible to inhibition by
certain huA3 isoforms. However, it is also possible that the virus rep-
licated ﬁrst in other rhesus cell types and then infected PBMC. Our re-
sults show that rhA3 can cause extensive mutations throughout
XMRV proviral sequences as well as introducing nonsense mutations
into the viral RT. The restriction effect of rhA3might have contributed
to the transient viremia that disappeared within 1 month from initial
infection. It is also worth noting that although XMRV sequences from
our analysis seem to be predominantly mutated by rhA3F, the two
rhesus macaques in our study displayed distinct mutation patterns
in terms of the nucleotide positions of G to A transition as well as fre-
quency. This suggested that similar to humans, the expression levels
of A3 proteins also vary between individual rhesus macaques (Koning
et al., 2009).
Our results suggest that A3 proteins will be potent inhibitors of
XMRV replication in PBMC of humans. Indeed, a recent study showed
little or no replication of XMRV in activated PBMC from humans in
which mutations at GG dinucleotide characteristic of A3G activity oc-
curred (Chaipan et al., 2011). It is unlikely that a virus that it is po-
tently inhibited by A3 could circulate in the human population. One
remote possibility is that XMRV might escape hypermutation by
infecting cell types that are deﬁcient in A3 proteins, such as prostate
cancer cells (Paprotka et al., 2010). Prostate provides a potential envi-
ronment for XMRV replication because its androgen rich environment
could drive viral transcription through an androgen response element
Fig. 3. Locations and numbers of A3-mediated G to A mutations in a 1.2 kb region of XMRV pol sequence (A) Nucleotide locations of G to Amutations in the 1.2 kb XMRV pol proviral
sequence from both rhesus macaques. The number of clones from RIl-10 (red) and RYh-10 (blue) that contains the speciﬁc mutation is labeled above the sequence. Codons mutated
by A3 to stop codons are shown in green. Mutated G nucleotides are underlined. (B) Shared and unique numbers of G to A mutations from both rhesus macaques depicted in a Venn
diagram generated online at the website http://jura.wi.mit.edu/bioc/tools/venn.php (Whitehead Institute for Biomedical Research, Cambridge, MA).
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Goff, 2010) and prostate cancer cells are often deﬁcient in A3G
(Paprotka et al., 2010). Moreover, during acute infection, the most
prominent XMRV replication observed in rhesus macaques was
in the prostate (Onlamoon et al., 2011; Sharma et al., 2011). Interest-
ingly, viremia was reactivated in monkey RIl-10 16 days after immu-
nization with a cocktail of recombinant XMRV proteins and
incomplete Freund's Adjuvant, suggesting potential reservoir sites
protected from the antiviral effect of APOBEC proteins (Onlamoon
et al., 2011).
Only less than 10% of the G to A mutations from our sequence anal-
ysis occurred in the GG dinucleotides context, mediated by rhA3G.
However, rhA3G exhibited potent (comparable to that of rhA3F) inhib-
itory effect on XMRV replication in a single cycle infectivity assay in
293T cells and was also capable of causing its signature mutations onXMRV proviral DNA in the same assay. One possible explanation is
that rhA3G might possess in vivo inhibitory mechanisms distinct from
simple editing. It has already been shown that hA3G is able to inhibit
HIV-1 cDNA accumulation in the absence of hypermutation possibly
by binding directly to viral RNA and impeding the translocation
of reverse transcriptase along its template (Bishop et al., 2008). Whe-
ther rhA3G shares similar properties with its human ortholog in
restricting XMRV replication will be an interesting topic for future
investigation.
In summary, in PBMC from XMRV infected rhesus macaques we
identiﬁed extensive G to A mutations in the context of GA and to a
lesser extent, at GC and GG dinucleotides. In addition, rhA3DE,
rhA3F and rhA3G strongly inhibited XMRV replication in single
cycle infectivity assay in 293 T cells. These data support a role for
rhA3 proteins in controlling XMRV spread in experimentally
Table 1
Stop codons generated by A3 mediated mutations in XMRV pol. (underlined nucleo-
tides indicate codons).
Nucleotide numbers
(relative positions
in the 1.2 kb pol
segment)
Initial
sequence
Sequence
after
infection
Presumptive
A3 isoform
responsible
for mutation
Number
of clones
223–226 TGGG TAGG A3G RIl-10: 1/18
RYh-10: 0/18
407–410 TGGA TGAA A3F RIl-10: 0/18
RYh-10: 8/18
641–644 TGGA TGAA A3F RIl-10: 6/18
RYh-10: 0/18
680–683 TGGA TGAA A3F RIl-10: 8/18
RYh-10: 0/18
962–965 TGGC TGAC A3DE RIl-10: 11/18
RYh-10: 0/18
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a similar effect of restricting XMRV infection in humans.
Materials and methods
XMRV inoculation of rhesus macaques
Methods of rhesus macaque inoculation with XMRV were described
previously (Onlamoon et al., 2011). In brief, two adult healthy rhesus
macaques (India origin) were housed at Yerkes National Primate Re-
search Center at Emory University and maintained in accordance with
the instructions of the Committee on the Care and Use of Laboratory An-
imals of the Institute of Laboratory Animal Resources, National Research
Council, and theU.S. Public Health Service (PHS) Guidelines,Guide for the
Care and Use of Laboratory Animals as described previously (Onlamoon
et al., 2011). XMRVwas grown in DU145 prostate cancer cells. Themon-
keys were inoculated with 3.6×106 TCID50 by the IV route. Blood was
collected by venipuncture at days 21 (male RIl-10) and 18 (female
RYh-10) post-infection. Peripheral blood mononuclear cells (PBMCs)
were puriﬁed through ﬁcoll density centrifugation.Fig. 4. The rhesus A3DE, A3G and A3F proteins inhibit XMRV infectivity and edit XMRV re
expressing the ﬁreﬂy luciferase pFB-Luc, the XMRV Gag-Pol expression plasmid pCAG/XGP,
BEC3 expression vectors. The empty parental vector was used as a control. Induced luciferase
are relative to cells transfected with the empty control plasmid, with standard deviations in
an antibody speciﬁc for the myc-tag present on each of the encoded A3 proteins. (B–F) Tot
shown for rhA3DE-I, rhA3DE-II, rhA3F, rhA3G, and empty control vector control transfecte
recognition sequences. These numbers were determined by sequencing 14 independent cDN
of the vector-encoded ﬁreﬂy luciferase gene.PCR ampliﬁcation of XMRV proviral DNA and sequence analysis
DNA from total PBMC was extracted using QIAamp Blood DNAMini
Kit followingmanufacturer's protocol (Qiagen). Nested PCRwas used to
amplify a 1.2 kb segment of the XMRV pol gene (2454–3656 nt) from
genomic DNA of PBMC with the following primers: 5′-ACCACGGATCG-
CAAAGTACA-3′ (ﬁrst round, forward); 5′-TTGCGTTAGGACGCCTTTGG-
3′ (ﬁrst round, reverse); 5′-TCACCCACTCTTTCCTCCATGTACC-3′ (sec-
ond round, forward) and 5′-GAGTTCAAAGGGCTTAGTCAAATCTGG-3′
(second round, reverse). Reactions in a total volume of 50 μl contained
100 to 250 ng genomic DNA, 2 μl of 25 mM MgCl2, 25 μl of HotStart-IT
FideliTaq Master Mix (USB Corporation, Cleveland, OH) and 0.75 μl of
each of 20 μM forward and reverses primers. PCR conditions were
94 °C for 4 min initial denaturation followed by 45 cycles consisting of
94 °C for 30 s, 57 °C for 30 s and 72 °C for 1.5 min with a ﬁnal extension
of 5 min at 72 °C. Five μl of ﬁrst round PCR products was used as tem-
plate in the second round PCR with the same reaction conditions.
Nested PCR without template were performed along with testing sam-
ples as a negative control to exclude possible contamination. PCR prod-
ucts were puriﬁed and cloned in pCR 2.1 TOP vector (Invitrogen, CA).
Positive clones were selected by colony PCR using the same second
round oligos. Eighteen positive clones were selected from eachmonkey
and sequenced followed by analysis using Hypermut program (Rose
and Korber, 2000).Assay for the effect of A3 proteins on XMRV infectivity
The assay to measure the effect of different human (hu) and rhe-
sus (rh) A3 proteins on XMRV infectivity were performed as previ-
ously described (Bogerd et al., 2011). HuA3G, huA3F, rhA3DE-I,
rhA3DE-II, rhA3G and rhA3F (Virgen and Hatziioannou, 2007) were
cloned into pCR1-3-based expression plasmids that expresses full-
length A3 protein linked to an amino-terminal Myc tag. XMRV virions
containing empty vector and each A3 protein were generated by co-
transfection of 293T cells of different A3 expression plasmids
(hA3G, rhA3B, rhA3DE-I, rhA3DE-II, rhA3G and rhA3F) with XMRV
Env (pCAG/XE), XMRV gag-pol (pCAG/XGP) expression clone andverse transcripts. (A) 293T cells were transfected with MLV-based indicator plasmid
the XMRV Env expressing plasmid pCAG/XE and the indicated human and rhesus APO-
levels in infect naïve 293T cells were assayed ~44 h later (upper panel). Data are given
dicated. The lower panel presents a Western Blot of the 293T virus producer cells using
al numbers and (G) the sequence context of these mutations were determined and are
d cells. GG→AA double mutations were not used in the determination of dinucleotide
A clones obtained from each infected cell culture, covering an identical 400-bp segment
33A. Zhang et al. / Virology 421 (2011) 28–33MLV based luciferase containing vector pFB-Luc (Stratagene). Condi-
tioned culture medium were harvested in 48 h, ﬁltered and used to
infect naïve 293T cells. Luciferase activity was measured about 44 h
post-infection. Expression of A3 proteins was monitored by Western
blot analysis of XMRV producer cell lysates using a rabbit anti-Myc
polyclonal antiserum (Abcam), followed by visualization using en-
hanced chemiluminescence.
Analysis of XMRV editing by rhesus A3 proteins in cell culture
To analyze editing of XMRV transcripts in by rhesus macaque A3
proteins in culture, total genomic DNAwas harvested 48 h after infec-
tion of 293T cells with XMRV virions containing rhA3DE-I, rhA3DE-II,
rhA3G or rhA3F. A total of 14 independent 400 bp segments of the
ﬁreﬂy luciferase gene were then recovered from genomic DNA by
PCR and subjected to sequence analysis as described above.
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